|
Oct 4
|
Sector Update: Health Care Stocks Steady Late Afternoon
|
|
Oct 4
|
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
|
|
Oct 4
|
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
|
|
Oct 4
|
J&J discontinues dengue drug study after changes in R&D portfolio
|
|
Oct 4
|
Wells Fargo says there is a risk that Johnson & Johnson will guide lower
|
|
Oct 4
|
Opdivo gets ‘perioperative’ approval; pharmas cut jobs in New Jersey, Ireland
|
|
Oct 4
|
2 Smart Income Stocks to Buy Right Now
|
|
Oct 3
|
Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today
|
|
Oct 2
|
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
|
|
Oct 2
|
ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
|
|
Oct 1
|
55-Year-Old Who Reached $3,900 Per Month Income In Just 5 Years Shares Portfolio: Top 9 Stocks And ETFs
|
|
Oct 1
|
J&J to invest over $2 billion for new manufacturing facility in North Carolina
|
|
Oct 1
|
Johnson & Johnson (NYSE:JNJ) is a favorite amongst institutional investors who own 73%
|
|
Oct 1
|
Johnson & Johnson launches TECNIS Odyssey intraocular lens in US
|
|
Oct 1
|
J&J drops 340B rebate plan following government pressure
|
|
Sep 30
|
J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program
|
|
Sep 30
|
Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45%
|
|
Sep 30
|
Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
|
|
Sep 30
|
J&J clinches EC approval for first single-pill PAH combo
|
|
Sep 30
|
80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024
|